Logo image of AMIX

AUTONOMIX MEDICAL INC (AMIX) Stock Fundamental Analysis

NASDAQ:AMIX - Nasdaq - US05330T2050 - Common Stock - Currency: USD

1.2  -0.04 (-3.23%)

After market: 1.2 0 (0%)

Fundamental Rating

2

Overall AMIX gets a fundamental rating of 2 out of 10. We evaluated AMIX against 187 industry peers in the Health Care Equipment & Supplies industry. While AMIX has a great health rating, there are worries on its profitability. AMIX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AMIX has reported negative net income.
AMIX had a negative operating cash flow in the past year.
AMIX Yearly Net Income VS EBIT VS OCF VS FCFAMIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 2025 -5M -10M -15M

1.2 Ratios

AMIX's Return On Assets of -116.35% is on the low side compared to the rest of the industry. AMIX is outperformed by 85.03% of its industry peers.
AMIX has a Return On Equity of -140.87%. This is in the lower half of the industry: AMIX underperforms 69.52% of its industry peers.
Industry RankSector Rank
ROA -116.35%
ROE -140.87%
ROIC N/A
ROA(3y)-170.19%
ROA(5y)N/A
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AMIX Yearly ROA, ROE, ROICAMIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 2025 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AMIX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AMIX Yearly Profit, Operating, Gross MarginsAMIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 2025

More info and screens

7

2. Health

2.1 Basic Checks

AMIX has more shares outstanding than it did 1 year ago.
AMIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMIX Yearly Shares OutstandingAMIX Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 2025 5M 10M 15M 20M
AMIX Yearly Total Debt VS Total AssetsAMIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -7.92, we must say that AMIX is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.92, AMIX is not doing good in the industry: 75.94% of the companies in the same industry are doing better.
AMIX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.92
ROIC/WACCN/A
WACCN/A
AMIX Yearly LT Debt VS Equity VS FCFAMIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

AMIX has a Current Ratio of 5.63. This indicates that AMIX is financially healthy and has no problem in meeting its short term obligations.
AMIX has a better Current ratio (5.63) than 79.68% of its industry peers.
A Quick Ratio of 5.63 indicates that AMIX has no problem at all paying its short term obligations.
AMIX has a Quick ratio of 5.63. This is amongst the best in the industry. AMIX outperforms 83.96% of its industry peers.
Industry RankSector Rank
Current Ratio 5.63
Quick Ratio 5.63
AMIX Yearly Current Assets VS Current LiabilitesAMIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 2025 2M 4M 6M 8M

More info and screens

0

3. Growth

3.1 Past

AMIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 60.54%, which is quite impressive.
EPS 1Y (TTM)60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AMIX will show a very negative growth in Earnings Per Share. The EPS will decrease by -52.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-202.11%
EPS Next 2Y-61.31%
EPS Next 3Y-52.54%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AMIX Yearly Revenue VS EstimatesAMIX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 200K 400K 600K 800K
AMIX Yearly EPS VS EstimatesAMIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 2028 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AMIX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMIX Price Earnings VS Forward Price EarningsAMIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMIX Per share dataAMIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

AMIX's earnings are expected to decrease with -52.54% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-61.31%
EPS Next 3Y-52.54%

More info and screens

0

5. Dividend

5.1 Amount

AMIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AUTONOMIX MEDICAL INC

NASDAQ:AMIX (8/8/2025, 8:18:58 PM)

After market: 1.2 0 (0%)

1.2

-0.04 (-3.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-29 2025-05-29/amc
Earnings (Next)N/A N/A
Inst Owners15.48%
Inst Owner Change0.25%
Ins Owners12.95%
Ins Owner Change0%
Market Cap6.06M
Analysts85
Price Target11.73 (877.5%)
Short Float %8.17%
Short Ratio0.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.66%
Min EPS beat(2)-43.68%
Max EPS beat(2)40.36%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-36.11%
EPS NQ rev (1m)29.59%
EPS NQ rev (3m)26.29%
EPS NY rev (1m)0%
EPS NY rev (3m)17.82%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-7.95
EYN/A
EPS(NY)-4.38
Fwd EYN/A
FCF(TTM)-1.64
FCFYN/A
OCF(TTM)-1.64
OCFYN/A
SpS0
BVpS1.6
TBVpS1.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -116.35%
ROE -140.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.19%
ROA(5y)N/A
ROE(3y)-217.4%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.65%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.63
Quick Ratio 5.63
Altman-Z -7.92
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.79%
EPS Next Y-202.11%
EPS Next 2Y-61.31%
EPS Next 3Y-52.54%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-24.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-24.22%
OCF growth 3YN/A
OCF growth 5YN/A